American International Group, Inc. Alpine Immune Sciences, Inc. Transaction History

American International Group, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$17.75 - $41.6 $49,061 - $114,982	2,764 Added 17.08%	18,949 $751,000
Q4 2023 Feb 13, 2024	BUY	$8.54 - $20.22 $2,929 - $6,935	343 Added 2.17%	16,185 $308,000
Q3 2023 Nov 13, 2023	BUY	$10.13 - $13.98 $5,703 - $7,870	563 Added 3.68%	15,842 $181,000
Q2 2023 Aug 04, 2023	BUY	$6.84 - $11.91 $26,409 - $45,984	3,861 Added 33.82%	15,279 $157,000
Q1 2023 May 12, 2023	BUY	$7.0 - $8.75 $4,956 - $6,195	708 Added 6.61%	11,418 $88,000
Q4 2022 Feb 10, 2023	BUY	$5.45 - $7.35 $17,957 - $24,218	3,295 Added 44.44%	10,710 $78,000
Q3 2022 Nov 14, 2022	BUY	$6.89 - $9.39 $723 - $985	105 Added 1.44%	7,415 $53,000
Q2 2022 Aug 12, 2022	BUY	$6.71 - $9.52 $10,353 - $14,689	1,543 Added 26.76%	7,310 $62,000
Q1 2022 May 13, 2022	SELL	$6.41 - $13.89 $2,602 - $5,639	-406 Reduced 6.58%	5,767 $52,000
Q4 2021 Feb 11, 2022	SELL	$10.41 - $13.95 $1,925 - $2,580	-185 Reduced 2.91%	6,173 $85,000
Q3 2021 Nov 12, 2021	SELL	$8.19 - $11.31 $1,236 - $1,707	-151 Reduced 2.32%	6,358 $68,000
Q2 2021 Aug 13, 2021	BUY	$8.81 - $15.03 $57,344 - $97,830	6,509 New	6,509 $59,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.